Patient and Family Member Reactions to Biomarker-Informed ADRD Diagnoses

患者和家属对基于生物标志物的 ADRD 诊断的反应

• 批准号: 10589205
• 负责人: Joshua Grill
• 金额: $ 211.2万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-01 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10589205
• 关键词: Address; African American; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer' s disease test; Alzheimer’s disease biomarker; Anxiety; Biological Markers; Black race; Clinical; Cognition Disorders; Cognitive; Demographic Factors; Diagnosis; Diagnostic; Emotional; Enrollment; Ethnic Origin; Evaluation; Family; Family member; Goals; Hispanic; Impaired cognition; Investigation; Latino; Learning; Life; Major Depressive Disorder; Medicare; Monitor; Nature; Not Hispanic or Latino; Observational Study; Participant; Patient Care; Patients; Pattern; Persons; Population; Population Heterogeneity; Protocols documentation; Publications; Reaction; Research; Resources; Risk; Safety; Sampling; Scanning; Site; Testing; amyloid imaging; beneficiary; clinical care; emotional distress; ethnic diversity; experience; patient response; psychologic; racial diversity; recruit; research clinical testing; response; sociodemographic factors; suicidal

Biomarkers of Alzheimer’s disease (AD) hold immense potential to impact clinical care of patients with cognitive disorders. Yet, the potentially life-altering nature of learning one’s AD biomarker status suggests that the burdens and benefits of such testing must be carefully balanced. Several studies of the personal implications of such testing have found that disclosing AD biomarker results does not cause clinical depression, anxiety, or suicidality. Most of this evidence has been derived from samples comprised of highly educated, cognitively healthy, non-Hispanic Whites who were scanned as part of a research protocol. There is pressing need to move beyond investigations of the psychological safety of disclosing biomarker results to highly selected research participants, to develop an understanding of the full range of burdens and benefits of AD biomarker testing in real-world populations. The proposed study will leverage a considerable opportunity to comprehensively characterize, within a large practice-based study of Medicare beneficiaries, patient responses to diagnoses of cognitive disorders that include AD biomarker testing. The New IDEAS study will enroll 7,000 Medicare beneficiaries at 350 sites throughout the US and provide amyloid imaging. At least 4,000 participants will be Black/African American or Hispanic/Latino, populations historically underrepresented in research on AD and related disorders (ADRD). The proposed study has been vetted and approved by the New IDEAS Research and Publications Committee. We will recruit 500 New IDEAS participants to enroll in a 6-month observational study to address the following Specific Aims. Aim 1. Quantify the range and patterns of emotional response to a biomarker-informed cognitive diagnosis, and determine which clinical or demographic factors are associated with specific responses. Aim 2. Characterize the “value of knowing” one’s AD biomarker status among symptomatic patients and their immediate family members. Aim 3. Identify the information and support needs of ethnically and culturally diverse families receiving biomarker-informed cognitive diagnoses. Our overarching hypothesis is that responses to biomarker-informed ADRD diagnoses are heterogeneous and associated with distinct clinical and sociodemographic factors. This study will advance the field’s understanding of real-world patient and family reactions to biomarker-informed ADRD diagnoses, providing critical information for directing post-diagnostic resources to monitor and support those most in need. Findings will inform best practices in the rapidly evolving state-of-the-art diagnostic evaluation of cognitive impairment.

阿尔茨海默病（AD）的生物标志物具有影响患者临床护理的巨大潜力